AAAAI 2021 Results of the SYNAPSE study for CRSwNP

Medscape ReCAP of new science at the American Rhinologic Society 2020 virtual meeting


Targeting Inflammation: Biologic Immunomodulators For Moderate-to-Severe Chronic Rhinosinusitis with Nasal Polyps – An Animated Whiteboard View

This enduring activity is focused on the care of patients with chronic rhinosinusitis with nasal polyps.

Stella E. Lee, MD


Chronic Rhinosinusitis with Nasal Polyps — Dupilumab, a New Therapy


Chronic Rhinosinusitis With Nasal Polyposis: Early Diagnosis

Chronic rhinosinusitis with nasal polyposis (CRSwNP) is a common condition that significantly affects quality of life and results in more than a million surgeries a year worldwide.

Symptoms of CRSwNP often mimic allergic rhinitis or bacterial rhinosinusitis, and patients frequently receive inappropriate prescriptions for allergy medications and even multiple courses of antibiotics. But appropriate therapeutic intervention can help to relieve CRSwNP symptoms, prevent unnecessary pain and suffering, reduce disease progression, and potentially prevent the need for nasal polypectomy.

Dr Stella Lee from the University of Pittsburgh discusses the importance of early and accurate diagnosis of CRSwNP, which is now viewed as a long-term, systemic inflammatory disorder, as well as strategies to assess symptom and disease severity.

References

nose.png
 
 

European Position Paper on Rhinosinusitis and Nasal Polyps 2020


Dexpramipexole depletes blood and tissue eosinophils in nasal polyps with no change in polyp size


EUFOREA consensus on biologics for CRSwNP with or without asthma


International Consensus Statement on Allergy and Rhinology: Rhinosinusitis


Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials